Phase I Trial of Camu Camu Prebiotic and Immune Checkpoint Inhibition in Patients With Non-Small Cell Lung Cancer and Melanoma
BR-2021-CamuCamu
NCT05303493
 Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Melanoma
Non Small Cells - Lung |
Dr. Nathalie Daaboul
Marilyn Tessier
450-466-5000 poste 7691
|
An Open-label, Multicenter, Phase 3 Randomized, Active-Comparator-Controlled Clinical Study of Pembrolizumab in Combination With Sacituzumab Govitecan Versus Pembrolizumab Monotherapy as First-line Treatment in Participants With PD L1 TPS Greater Than or Equal to 50% Metastatic Non-small Cell Lung Cancer
MK-3475-D46 (KEYNOTE D46/EVOKE-03)
NCT05609968
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Non Small Cells - Lung |
Dr. Nathalie Daaboul
Marilyn Tessier
450-466-5000 poste 7691
|
A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer
M18-868
NCT04928846
Recruiting
|
CISSS DE LA MONTEREGIE-CENTRE
HOPITAL CHARLES-LE MOYNE
|
Non Small Cells - Lung |
Dr. Nathalie Daaboul
Marie-Ève Yelle
450-466-5000 poste 3281
|
Groupe d'étude en oncologie du Québec